# colorectal cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 38838
- Completion tokens: 17221
- Reasoning tokens: 0
- Total tokens: 56059
- API requests reported: 3
- Elapsed seconds: 247.912
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: OpenAI

---
## Data-quality and statistical scope

This is a **prognostic survival analysis**, not a differential-expression analysis; therefore, the results support associations between gene measurements and overall survival, not claims that genes are transcriptionally upregulated or downregulated in colorectal cancer.

The ledger contains **100 unique genes** and **209 retained input rows**, including **53 duplicated or grouped probe/gene rows**. There are **54 risk-associated genes (HR > 1)** and **46 protective-associated genes (HR < 1)**. Seventy-one genes have FDR ≤ 0.05, but only eight have FDR ≤ 0.01. Direction conflicts are recorded for **DCBLD2**, **LOC101928747|RBMX|SNORD61**, and **BCL2L14**, so these should not be treated as stable single-gene markers without probe-level resolution. The retrieved pathway and network records were not recomputed here and are annotations rather than additional statistical tests. **External statistical validation was not performed**: no independent-cohort HR, P value, FDR, or survival model was supplied.

## 1. Overall biological interpretation

The most coherent interpretation is that poorer OS is associated with a tumor state combining:

- **Extracellular-matrix, adhesion, cytoskeletal, and possible invasive remodeling**, represented by risk-associated **INHBB, DCBLD2, ITGBL1, PTPN14, TPM4, ABL2, SCEL, NT5E, and MSLN**.
- **Reduced intestinal epithelial differentiation**, with protective associations for **CDX2** and **MYO5B**, and weaker protective associations for **CDX1** and **LGALS4**.
- **Preserved mitochondrial and intermediary metabolic capacity**, represented by protective associations for **ATP23, NDUFA9, CS, ILVBL, MCCC2, COA3, ATP5B, ATP5G1, OGDHL, and GLYCTK**.
- A potentially important but unresolved **immune–stromal component**, because **NT5E** is risk-associated whereas **TAPBPL, LGALS9, CCL15, and CCL14** are protective-associated.

Thus, the data are more consistent with a **multidimensional tumor-state and tissue-composition signature** than with one dominant oncogenic pathway. The associations may reflect malignant-cell biology, stromal remodeling, immune-cell abundance, tumor purity, or combinations of these factors.

## 2. Core biological programs

### Program 1: Extracellular-matrix remodeling, adhesion, and invasive tumor state

- **Association:** Predominantly risk-associated.
- **Supporting genes:** **INHBB** HR=1.433, FDR=0.001093; **DCBLD2** HR=1.408, FDR=0.008647; **TPM4** HR=1.364, FDR=0.008910; **PTPN14** HR=1.362, FDR=0.025013; **ITGBL1** HR=1.299, FDR=0.030610; **ABL2** HR=1.301, FDR=0.027572; **SCEL** HR=1.254, FDR=0.039391; **NT5E** HR=1.313, FDR=0.039391; **MSLN** HR=1.313, FDR=0.045071.
- **Relevant standardized pathways:** Reactome **Extracellular matrix organization**, **Cell–cell junction organization**, and **Integrin-mediated cell adhesion**; GO terms related to cell adhesion, extracellular matrix organization, and actin-cytoskeleton remodeling. These pathway labels are mechanistically appropriate interpretations, not formal enrichment results from this table.
- **Interpretation:** The convergence of matrix-associated genes, adhesion regulators, actin-related **TPM4**, signaling-associated **ABL2/PTPN14**, and the glycoprotein-associated genes **ITGBL1, DCBLD2, and MSLN** supports a tumor microenvironment or tumor-cell state characterized by altered adhesion and tissue remodeling. This could facilitate invasion or reflect a desmoplastic, stromally rich tumor.
- **Evidence strength:** **Moderate supported hypothesis** from multiple concordant risk-associated genes, with pathway and interaction annotations providing plausibility. **INHBB** has particularly strong direct statistical evidence and is also supported by a colorectal-cancer literature record associating high expression with poor prognosis and malignant phenotypes (Europe PMC **PMID: 41992239**).
- **Limitations:** The analysis does not establish invasion, matrix deposition, or causality. Several genes may be expressed by stromal or mesothelial populations rather than malignant epithelial cells. The duplicated and conflicting probe structure for **DCBLD2** is an additional concern.

### Program 2: Intestinal epithelial differentiation and epithelial architecture

- **Association:** Protective-associated overall, although not every member passes FDR ≤ 0.05.
- **Supporting genes:** **CDX2** HR=0.748, FDR=0.035501; **MYO5B** HR=0.748, FDR=0.028228; **LGALS4** HR=0.771, FDR=0.051227; **CDX1** HR=0.781, FDR=0.057346; **CCL15** HR=0.753, FDR=0.035501.
- **Relevant standardized pathways:** GO **epithelial cell differentiation**, **intestinal epithelial cell differentiation**, and **cell–cell junction organization**; Reactome intestinal epithelial differentiation-related processes where gene mapping is available.
- **Interpretation:** The joint protective direction of **CDX2, CDX1, MYO5B, and LGALS4** is compatible with retention of intestinal epithelial identity and architecture being associated with better OS. This is biologically plausible in colorectal cancer, but the result should be interpreted as a survival association rather than proof that differentiation itself is protective.
- **Evidence strength:** **Supported hypothesis.** Direct dataset evidence is coherent for several epithelial genes. Published evidence supports a mechanistic role for CDX2 in colon cancer models through suppression of Wnt/β-catenin signaling (PMID **30631044**), but that experimental evidence is not an independent survival validation of this cohort.
- **Limitations:** **CDX1, LGALS4, and other genes are just above FDR 0.05**, and epithelial-marker abundance can be strongly influenced by tumor purity. **CCL15** may have immune or stromal contributions and should not be treated as a pure epithelial marker.

### Program 3: Mitochondrial respiration and intermediary metabolism

- **Association:** Predominantly protective-associated.
- **Supporting genes:** **ATP23** HR=0.688, FDR=0.006636; **NDUFA9** HR=0.689, FDR=0.008647; **GLYCTK** HR=0.709, FDR=0.020342; **CS** HR=0.754, FDR=0.038754; **ILVBL** HR=0.725, FDR=0.032941; **MCCC2** HR=0.739, FDR=0.028227; **COA3** HR=0.744, FDR=0.043365; **ATP5B** HR=0.748, FDR=0.059305; **ATP5G1** HR=0.747, FDR=0.051935; **OGDHL** HR=0.686, FDR=0.074430.
- **Relevant standardized pathways:** Reactome **Respiratory electron transport**, **Citric acid cycle**, and **Mitochondrial protein complex assembly**; KEGG **Glycine, serine and threonine metabolism** and **Fructose metabolism** for GLYCTK-related annotation.
- **Interpretation:** Multiple mitochondrial respiratory-chain, ATP-synthase, TCA-cycle, and amino-acid or carbon-metabolism genes show HR < 1. This suggests that higher expression of a mitochondrial/metabolic competence program is associated with better OS in this dataset, whereas reduced representation of this program may mark aggressive, poorly differentiated, or metabolically stressed tumors.
- **Evidence strength:** **Moderate supported hypothesis**, because the direction is repeated across several functionally related genes and matches Reactome/GO annotations. The GLYCTK annotation links it to glycerate, fructose, and serine metabolism. A STRING relationship between **COA3** and **ILVBL** is network evidence, not proof of direct physical binding.
- **Limitations:** Bulk-tissue mitochondrial expression is highly sensitive to cellular composition, necrosis, stromal content, and tumor purity. No metabolomic or mitochondrial functional measurements were provided, and the pathway recurrence is not a formal enrichment P value.

### Program 4: Immune–purinergic and T-cell-migration-related microenvironment

- **Association:** Mixed and therefore unresolved at the program level.
- **Supporting genes:** Risk-associated **NT5E** HR=1.313, FDR=0.039391 and **NPR3** HR=1.350, FDR=0.016424; protective-associated **TAPBPL** HR=0.711, FDR=0.019210, **LGALS9** HR=0.753, FDR=0.042039, and **CCL15** HR=0.753, FDR=0.035501.
- **Relevant standardized pathways:** GO **Regulation of T-cell migration** (GO:2000404) and purinergic signaling-related processes involving NT5E/CD73. The retrieved GO term is contextual annotation, not an enrichment calculation.
- **Interpretation:** The opposing directions suggest that survival may depend on the balance between immune-cell recruitment or activation and an immunosuppressive extracellular-adenosine environment. **NT5E** is a plausible marker of an immunoregulatory tumor microenvironment; literature has proposed CD73/NT5E as a cancer prognostic and immunotherapy biomarker across tumor types (PMID **36480312**). However, protective **TAPBPL, LGALS9, and CCL15** prevent a simple “immune activation is favorable” conclusion.
- **Evidence strength:** **Exploratory hypothesis.** The direct survival associations and retrieved GO annotation support investigation, but there is no immune deconvolution, cell-type-specific expression, or treatment-response analysis.
- **Limitations:** These genes may primarily report immune, endothelial, or stromal abundance. Literature across multiple cancer types may not transfer to colorectal cancer or to this treatment context.

### Program 5: Cytoskeletal and microtubule-organizing-center remodeling

- **Association:** Predominantly risk-associated.
- **Supporting genes:** **TPM4** HR=1.364, FDR=0.008910; **NIN** HR=1.345, FDR=0.028228; **MAP1B** HR=1.327, FDR=0.047204; **ABL2** HR=1.301, FDR=0.027572; **LRCH3** HR=1.341, FDR=0.040615; **LRCH1** HR=1.337, FDR=0.059876; **GJB6** HR=1.290, FDR=0.039377.
- **Relevant standardized pathways:** GO **Microtubule anchoring at the microtubule organizing center** (GO:0072393), **actin filament organization**, and cell-motility-related processes.
- **Interpretation:** The combination of actin-associated **TPM4**, centrosomal or microtubule-organizing gene **NIN**, and signaling/cytoskeletal regulators is compatible with altered cell shape, migration, polarity, or mitotic organization in higher-risk tumors.
- **Evidence strength:** **Exploratory to moderate hypothesis.** The current data provide a repeated risk direction and the retrieved GO term is biologically coherent. STRING records connect **LRCH1/LRCH3** to DOCK-family proteins, but these are network associations and do not demonstrate a direct interaction among the selected genes.
- **Limitations:** This program overlaps with the matrix/adhesion interpretation and may represent a general proliferation or tissue-structure signal rather than a specific invasion mechanism.

## 3. Key genes and interaction modules

1. **INHBB** — Risk-associated, HR=1.4332849, P=1.9993823e-08, FDR=0.0010931622. It is the strongest statistically supported candidate and fits the matrix/remodeling and growth-factor signaling interpretation. External colorectal-cancer literature also supports poor-prognosis and malignant-phenotype associations (Europe PMC PMID **41992239**). This remains an association; causal INHBB activity was not tested.

2. **DCBLD2** — Risk-associated representative HR=1.4080371, P=9.8603656e-07, FDR=0.0086471166, but the ledger records **direction conflict across four rows**. It is therefore a high-priority probe-resolution candidate, potentially related to cell-surface signaling and matrix biology. The relationship to INHBB or ITGBL1 is best described as **pathway co-membership or indirect association**, not direct physical interaction.

3. **ITGBL1–PTPN14–ABL2 module** — **ITGBL1** HR=1.2990094, FDR=0.0306095; **PTPN14** HR=1.3616616, FDR=0.0250133; **ABL2** HR=1.3012167, FDR=0.0275721. Together they suggest adhesion, phosphotyrosine signaling, and cytoskeletal remodeling. The evidence supports **functional/pathway co-membership and a putative regulatory relationship**, not a demonstrated physical complex.

4. **TPM4–NIN–MAP1B module** — All are risk-associated: TPM4 HR=1.3635104, NIN HR=1.345184, and MAP1B HR=1.3274716. This is a plausible **cytoskeletal and microtubule-organizing module**. Their relationship is primarily **pathway co-membership and indirect functional association**; no direct physical interaction among all three is supplied.

5. **NT5E** — Risk-associated, HR=1.3129820, P=4.3264551e-05, FDR=0.0393907. It is a candidate marker of an immunoregulatory, purinergic microenvironment. The relationship to **TAPBPL, LGALS9, and CCL15** is best described as **immune-pathway co-membership or indirect microenvironmental association**, not direct binding.

6. **CDX2–CDX1–MYO5B–LGALS4 module** — CDX2 HR=0.74776163, FDR=0.0355019; MYO5B HR=0.74832371, FDR=0.028228; CDX1 HR=0.78085163, FDR=0.0573456; LGALS4 HR=0.77119484, FDR=0.0512272. This is a protective-associated epithelial-differentiation module. CDX2’s documented regulatory relationship with intestinal differentiation and Wnt-related transcription is literature-supported (PMID **30631044**), whereas relationships among all four genes are chiefly **co-expression or pathway co-membership**.

7. **ATP23–NDUFA9–COA3 module** — ATP23 HR=0.68848836, FDR=0.0066356; NDUFA9 HR=0.68863259, FDR=0.0086471; COA3 HR=0.74374187, FDR=0.0433648. This is a strong protective-associated mitochondrial module. ATP23 has mitochondrial ATP-synthase processing/chaperone annotation, with related interaction literature (PMID **17135288**), but that record is not colorectal-cancer survival validation. The module reflects **functional co-membership**, not necessarily direct interaction.

8. **GLYCTK–CS–ILVBL metabolic module** — GLYCTK HR=0.70929051, FDR=0.0203419; CS HR=0.75447917, FDR=0.0387542; ILVBL HR=0.72456474, FDR=0.0329410. These genes support carbon, TCA, and amino-acid metabolism. STRING reports selected-gene relationships involving **CS** with **ACSS2/ILVBL**, but the exact relationship type is database-dependent and should be regarded as **predicted or functional network association**, not direct physical binding.

9. **MIR31HG–ZEB1-AS1–NR2F1-AS1 lncRNA group** — All are risk-associated representatives: MIR31HG HR=1.3093772, FDR=0.0066356; ZEB1-AS1 HR=1.3719515, FDR=0.0086471; NR2F1-AS1 HR=1.3141394, FDR=0.0355019. This suggests a possible transcriptional or epigenetic regulatory state, but the supplied evidence does not establish shared regulation or a common mechanism. The relationship is **putative regulatory co-occurrence**, with insufficient evidence for a direct lncRNA interaction module.

10. **LINC00852** — Protective-associated in this dataset, HR=0.7409645, P=0.00014498, FDR=0.0720621, therefore not FDR-significant at 0.05. A lung-cancer publication associated LINC00852 with poor prognosis and chemoresistance (PMID **34342374**), which conflicts with the direction here and may reflect tissue- or disease-specific biology. It should remain an **exploratory, not validated, candidate**.

## 4. Validation priorities

### 1. INHBB-driven stromal or malignant-cell remodeling  
**Classification:** Mechanistic hypothesis

- **Why prioritize:** INHBB has the strongest direct statistical signal, HR=1.4332849 and FDR=0.0010931622, and is supported by a colorectal-cancer literature record.
- **Current evidence:** Risk association in the present tumor-tissue cohort.
- **External evidence:** Europe PMC PMID **41992239** supports poor prognosis and malignant phenotypes, but this is literature support rather than an independent statistic supplied for this analysis.
- **Next step:** Validate INHBB protein and cellular localization by immunohistochemistry or spatial transcriptomics, then test perturbation in colorectal cancer organoids and matched stromal co-cultures.
- **Conclusion level:** **Supported hypothesis**, not established causality.

### 2. Differentiation-preserving CDX2/CDX1 epithelial state  
**Classification:** Biomarker

- **Why prioritize:** The coherent protective direction of CDX2, CDX1, MYO5B, and LGALS4 could define a clinically useful differentiation-associated survival signature.
- **Current evidence:** CDX2 and MYO5B meet FDR ≤ 0.05; CDX1 and LGALS4 are directionally supportive but have FDR > 0.05.
- **External evidence:** CDX2 has experimental colon-cancer evidence involving Wnt/β-catenin suppression (PMID **30631044**).
- **Next step:** Test the module in an independent colorectal cancer cohort with stage, grade, molecular subtype, and treatment adjustment; validate protein-level differentiation and tumor purity.
- **Conclusion level:** **Supported hypothesis**.

### 3. NT5E-centered immune–purinergic microenvironment  
**Classification:** Biomarker and mechanistic hypothesis

- **Why prioritize:** NT5E is risk-associated at FDR=0.0393907 and provides a plausible link between tumor tissue, extracellular adenosine, and immune suppression.
- **Current evidence:** NT5E risk association, with opposing associations for TAPBPL, LGALS9, and CCL15.
- **External evidence:** PMID **36480312** supports NT5E as a broad cancer prognostic/immunotherapy biomarker, but source overlap and disease heterogeneity limit independence.
- **Next step:** Perform immune deconvolution or spatial profiling, quantify CD73/NT5E protein and extracellular adenosine, and test association with immune infiltrates and treatment exposure.
- **Conclusion level:** **Exploratory hypothesis**, because the directionally mixed immune program is unresolved.

### 4. Mitochondrial competence as a protective survival state  
**Classification:** Biomarker

- **Why prioritize:** ATP23 and NDUFA9 are among the most statistically robust protective genes, and several additional mitochondrial/metabolic genes show concordant HR < 1.
- **Current evidence:** ATP23 HR=0.68848836, FDR=0.0066356; NDUFA9 HR=0.68863259, FDR=0.0086471; additional support from CS, ILVBL, MCCC2, and COA3.
- **External evidence:** Reactome and gene annotations support mitochondrial and metabolic functions; these records do not constitute survival replication.
- **Next step:** Validate the signature in independent cohorts and measure mitochondrial respiration, ATP production, and metabolite profiles in tumor organoids or freshly isolated tumor cells.
- **Conclusion level:** **Supported hypothesis**, with substantial composition-related uncertainty.

### 5. Probe identity, tumor purity, and cell-composition effects  
**Classification:** Confounding or composition check

- **Why prioritize:** The table contains 53 duplicated/grouped rows, and DCBLD2 has direction-conflicting rows. Bulk tumor tissue can also combine epithelial, immune, stromal, endothelial, and mesothelial signals.
- **Current evidence:** Direction conflicts and mixed lineage-associated programs, particularly the epithelial, immune, matrix, and metabolic patterns.
- **External evidence:** Tissue-expression and pathway annotations support multiple possible cellular sources, but no cell-resolved validation was supplied.
- **Next step:** Re-map probes to current gene models, inspect probe-level survival curves, repeat multivariable Cox models adjusted for stage, age, sex, treatment, purity, and immune/stromal scores, and use single-cell or spatial data.
- **Conclusion level:** **Established analytical necessity**, while the biological interpretation remains conditional.

## 5. Limitations and alternative explanations

1. **No independent statistical replication:** pathway recurrence, literature, STRING edges, and database annotations do not replace an external cohort HR or FDR. Therefore, prognostic generalizability is currently unconfirmed.

2. **Bulk-tissue composition and tumor purity:** Protective epithelial genes may indicate a larger differentiated epithelial fraction, while risk-associated matrix or NT5E signals may indicate stromal, endothelial, mesothelial, or immune composition. This can be investigated with purity estimates, immune/stromal deconvolution, single-cell RNA-seq, spatial transcriptomics, and protein co-localization.

3. **Clinical confounding:** OS associations may reflect stage, metastatic burden, age, sex, treatment exposure, molecular subtype, or postoperative therapy rather than intrinsic gene effects. Multivariable and stratified survival models are required.

4. **Probe duplication and annotation uncertainty:** Multiple probe or grouped-locus rows can inflate apparent support, and the direction conflict for DCBLD2 is especially important. Probe re-annotation and probe-specific analysis should precede clinical-marker development.

5. **Association-versus-causation and pathway breadth:** The identified programs are biologically plausible but broad. A risk-associated gene may be a marker of an aggressive state rather than a driver, and a protective-associated gene may reflect healthier tissue composition rather than a protective mechanism. Functional perturbation and prospective validation are needed before therapeutic claims are made.

Overall, the strongest current signal is a **risk-associated matrix/adhesion state centered on INHBB and related remodeling genes, opposed by protective epithelial-differentiation and mitochondrial-metabolic programs**, while the immune interpretation remains mixed and requires cell-resolved validation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=128, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
